Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

Clinical relevance of circulating cell-free microRNAs in cancer

(2014) Heidi Schwarzenbach et al.   Nature Reviews Clinical Oncology

High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer

(2014) Simone Anfossi et al.   PLoS One

Circulating miR-200c Levels Significantly Predict Response to Chemotherapy and Prognosis of Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Cancer

(2013) Koji Tanaka et al.   ANNALS OF SURGICAL ONCOLOGY

The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab

(2013) Kojiro Eto et al.   ANNALS OF SURGICAL ONCOLOGY

Treatment of HER2-positive breast cancer

(2013) Maria Cristina Figueroa-Magalhães et al.   BREAST

Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression

(2013) C. Eichelser et al.   CLINICAL CHEMISTRY

Increased Expression of MicroRNA-21 and Its Association with Chemotherapeutic Response in Human Colorectal Cancer

(2013) K Liu et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls

(2012) Zhibin Hu et al.   CARCINOGENESIS

The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors

(2012) Bing Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

(2011) Eun-Jung Jung et al.   CANCER

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

(2011) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells

(2011) Mingli Han et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases

(2009) Maria Angelica Cortez et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma

(2008) Charles H. Lawrie et al.   BRITISH JOURNAL OF HAEMATOLOGY

The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

(2008) Qihong Huang et al.   NATURE CELL BIOLOGY